Detail Sample Clauses

Detail. Midstream Co shall cause its invoices and supporting information to include information reasonably sufficient to explain and support any estimates and charges reflected therein, the reconciliation of any estimates made in a prior Month to the actual measurements for such Month, and any adjustments to prior period volumes and quantities.
Detail or "Detailing" means, with respect to a Collaboration ------ ---------
Detail. OR "DETAILING" shall mean, with respect to a Collaboration Product, an interactive face-to-face visit by a Party's sales representative with a physician, designated by the Commercial Lead as a member of the target call audience, at his or her office, at hospitals or at other locations (excluding exhibits, displays and other forms of communication not involving face-to-face contact by such sales representative), during which indicated uses, safety, effectiveness, contraindications, side effects, warnings and/or other relevant characteristics of a Collaboration Product as approved by a Regulatory Authority are described in a fair and balanced manner consistent with the FD&C Act (or equivalent laws in the Territory), as applicable, including, but not limited to, the regulations at 21 CFR Part 202 and using, as necessary or desirable, the Product Labeling (as defined herein) or the Promotional Materials (as defined herein), in an effort to increase physician prescribing preferences of such Collaboration Product for its approved indicated uses.
Detail or “Detailing” means, with respect to a Collaboration Product, the communication by a Sales Representative during a Sales Call (a) involving face-to-face contact or by means of an e-detail or detailing through video, (b) describing in a fair and balanced manner the FDA-approved indicated uses and other relevant characteristics of such Collaboration Product, (c) using the Promotional Materials in an effort to increase the prescribing and/or hospital ordering preferences of a Collaboration Product for its FDA-approved indicated uses, and (d) made at such medical professional’s office, in a hospital, at marketing meetings sponsored by a Party for the Collaboration Products or other appropriate venues conducive to pharmaceutical product informational communication where the principal objective is to place an emphasis, either primary or secondary, on a Collaboration Product and not simply to discuss a Collaboration Product with such medical professional. For the avoidance of doubt, discussions at conventions or other meetings not specifically sponsored by a Party for a Collaboration Product shall not constitute “Details” or “Detailing”.
Detail or “Detailing” means, with respect to a Licensed Product, the communication by a Sales Representative to a Prescriber during a sales call (a) involving face-to-face contact or, if permitted by the Co-Detailing Agreement, contact by means of an e-detail or video, (b) describing in a fair and balanced manner the FDA-approved indicated uses and other relevant characteristics of such Licensed Product, (c) using the Promotional Materials in an effort to inform Prescribers about a Licensed Product for its FDA-approved indicated uses, and (d) made at such Prescriber’s office, at another appropriate alternate care setting, or in any other venue as described in the Co-Detailing Agreement and consistent with Applicable Law, the Co-Detailing Agreement and other industry standards. For the avoidance of doubt, discussions at conventions or other scientific meetings shall not constitute “Details” or “Detailing”.
Detail or “Detailing” shall mean, with respect to the Product, the activity undertaken by a Sales Representative during a Call in which one or more Product benefits are verbally presented to one or more Target Audience in accordance with the applicable Operational Commercialisation Plan, but shall exclude discussions at conventions, marketing meetings or seminars, and all forms of communication not involving face-to-face contact by a Sales Representative and a member of the Targeted Audience.
Detail or “Detailing” means a face-to-face meeting (including a live video presentation but not including Promotion Related Activities) in the Co-Promotion Territory between a Party’s Sales Representative and (a) a medical professional with prescribing authority or other individuals or entities that have a significant impact/influence on prescribing decisions or (b) such other groups as may be mutually agreed by the Parties, during which the Sales Representative provides an oral presentation of an Initial Licensed Product’s attributes in a fair and balanced manner consistent with the requirements of this Agreement and Applicable Law and in a manner that is customary in the industry for the purpose of promoting a prescription pharmaceutical product. When used as a verb, “Detail” shall mean to engage in the activities set forth in this paragraph.
Detail or “Detailing” means each separate face-to-face contact by a professional sales representative with a physician or other professional with authority to write prescriptions during which time the promotional message involving the Product is presented and is a topic of discussion and/or a sample of the Product is left with the physician or such other professional. When used as a verb, “Detail” shall mean to engage in a Detail.
Detail or “Detailing” means, with respect to the Product and/or any Additional Product in the Territory, communication by a Sales Representative during a Sales Call (i) in an effort to increase the prescribing and/or hospital ordering preferences of such Products and/or any Additional Products for their respective FDA-approved indicated uses and (ii) made at a medical professional’s office, in a hospital, at marketing meetings sponsored by a Party for the Product and/or any Additional Product, where the principal objective is to place an emphasis, either primary, secondary or tertiary, on the Product and/or any Additional Product. For the avoidance of doubt, discussions at conventions or other meetings not specifically sponsored by a Party for the Product or any Additional Product shall not constitute “Details” or “Detailing”.